{
  "docId": "019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "docSlug": "4fd785179c9b78e08eb8c823d8e306e6",
  "documentTitle": "argenx SE | Results Presentation Deck | 24 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 24,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "other",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a process flow diagram to illustrate the clinical trial stages.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-f8c0-72fa-b47b-4b134ca99d3b/9",
  "deckHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b",
  "deckJsonHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b.json",
  "deckAnchorHref": "/decks/019de070-f8c0-72fa-b47b-4b134ca99d3b#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.78,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Primary endpoint is proportion of PV patients achieving CRmin* within 30 weeks. N=sample size estimation ≤150 patients (PV and PF) with PF patients capped. Followed by Open Label Extension study",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "767c964b-b201-4d6b-8954-d7d683329696",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.75,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Screening to Randomization process flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e76ac4d-244c-4420-91f1-2a863be4f42c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "CR=complete clinical remission; CRmin=complete remission on minimal therapy; EoC=end of consolidation; SC=subcutaneous.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "565ec7c1-624c-4cd7-9232-25ca490d8394",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Efgartigimod Phase 3 Trial in Pemphigus - Focus on Potential to Drive Fast-Onset and Steroid Sparing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "655ee664-f130-45e5-8d8c-fdab2fc91cde",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 5,
      "beatId": "14f2a1bd-eacd-4305-b248-ea3710f3a72b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 5-10 present Efgartigimod as a solution.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}